Results for: Outperform Rating

Despite challenges faced by the gaming industry, Oppenheimer remains optimistic about Electronic Arts’ prospects, maintaining its Outperform rating and $150.00 price target. While acknowledging recent underperformance of ‘Apex Legends’ and moderating fiscal year 2025 forecasts, the firm suggests potential catalysts in the latter half of 2024 that could make Electronic Arts an attractive investment compared to its peer Take-Two Interactive. Oppenheimer’s analysis points to the company’s strong market position, portfolio of popular gaming franchises, and strategic positioning as key factors driving its positive outlook.

Corporate bond research firm Gimme Credit has reaffirmed its Outperform recommendation on Netflix bonds, particularly the 2030 notes. The firm attributed this rating to the streaming giant’s emphasis on original content, which has driven revenue growth and subscriber engagement. Netflix’s substantial investment in content has yielded notable results, with its offerings dominating the charts and resonating with a global audience. Furthermore, Gimme Credit projects Netflix’s revenue growth to exceed 14% this year, supported by its crackdown on password sharing. The company’s financial performance has also been impressive, with a significant lead in subscribers, earnings, and free cash flow. The reversal of negative free cash flow and the accumulation of cash reserves indicate Netflix’s improved financial health. The Outperform rating reflects Gimme Credit’s confidence in Netflix’s strategic direction and financial strength.

Oppenheimer analyst Timothy Horan continues to recommend Verizon Communications Inc. (VZ) with an Outperform rating and a $48 price target. Horan highlights the company’s positive momentum driven by network upgrades, refreshed management, and improved go-to-market strategy. Verizon’s first-quarter results were impacted by January price increases affecting volumes. However, one-time expenses also contributed to the results, setting the stage for solid free cash flow (FCF) growth. Horan believes Verizon’s ARPA growth of 3.9% will continue, driven by pricing and the expansion of recurring revenue streams. While subscriber growth remains a priority, Horan expects tougher year-on-year comparisons in the second half. Despite trimming revenue estimates, Horan maintains his FCF estimates for 2024 and 2025. Verizon’s stock has gained 8% in the past 12 months and is available through ETFs such as DJD and FDL.

RBC Capital Markets has initiated coverage of Ultragenyx Pharmaceutical (NASDAQ: RARE) with an outperform rating and a $77 price target, suggesting 82% upside potential from current levels. The analyst sees a favorable risk/reward profile, citing an undemanding valuation and a clear path to profitability if any of the late-stage pipeline drugs are successful. Ultragenyx’s base business continues to grow at a steady pace, providing downside protection.